Meanwhile, a recent preclinical study has found that targeting CD276 by CAR-T cells effectively inhibited PDAC tumor growth in vitro and in vivo (Du et al., 2019), suggesting the potential efficacy in a selected subgroup of PDAC patients. Here, CD276 is linked to neoplasm.